Article
KRAS Inhibition in Pancreatic Cancer: Pooled Efficacy and Safety Signals from Early-Phase Studies
2025-12-04
Abstract excerpt
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers, driven by KRAS mutations long deemed “undruggable”. We conducted a meta-analysis of five early phase cohorts (n=301) that evaluated KRAS-targeted therapies in patients with PDAC. The pooled objective response rate was 28% (95% CI 22–35%), indicating promising activity in refractory PDAC, with consistent estimates across the studies (I...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- be4c43ba-9f73-5100-82bb-43060ec3e54a
- DOI
- 10.64898/2025.12.03.25341547